Literature DB >> 15603858

Long-term survivors in stage IV non-small cell lung cancer.

Tatsuro Okamoto1, Riichiroh Maruyama, Fumihiro Shoji, Hiroshi Asoh, Jiro Ikeda, Tetsuya Miyamoto, Tomomi Nakamura, Tetsuro Miyake, Yukito Ichinose.   

Abstract

BACKGROUND AND OBJECTIVES: To determine the prognostic factors for long-term survivors (LTS) with stage IV non-small cell lung cancer (NSCLC) who had undergone various treatments. PATIENTS AND METHODS: From 1990 to 1999, 222 NSCLC patients with stage IV disease, who had been treated in our department, were reviewed. As the initial treatment, 135 patients (48%) were treated with chemotherapy alone, 52 patients with a combination of chemotherapy and radiotherapy, 19 patients underwent an operation with or without any other therapeutic modalities and 16 were received radiotherapy alone.
RESULTS: Seventeen (7.7%) patients survived for more than 2 years, and all but one had adenocarcinoma. Among these LTS, eight patients received surgery as the initial therapy, and 16 (94.1%) received some type of local-control therapy, including surgery or radiotherapy, during the course of their disease. Regarding the clinical characteristics between LTS and others (non-LTS), an early N status, a single metastatic site, a good performance status, and surgery for initial therapy were all found to be significantly important factors for LTS. A multivariate analysis using a logistic regression model also showed an early N status and surgical treatment to be significantly associated with LTS.
CONCLUSIONS: Selected patients with an early N status may be appropriate candidates for aggressive multimodality treatment including surgery, in order to provide a long-term survival for stage IV NSCLC.

Entities:  

Mesh:

Year:  2005        PMID: 15603858     DOI: 10.1016/j.lungcan.2004.06.006

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  11 in total

1.  Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Authors:  Jessica J Lin; Stephanie Cardarella; Christine A Lydon; Suzanne E Dahlberg; David M Jackman; Pasi A Jänne; Bruce E Johnson
Journal:  J Thorac Oncol       Date:  2015-12-25       Impact factor: 15.609

2.  Sleep and quality of life in long-term lung cancer survivors.

Authors:  Nalaka S Gooneratne; Grace E Dean; Ann E Rogers; J Emeka Nkwuo; James C Coyne; Larry R Kaiser
Journal:  Lung Cancer       Date:  2007-08-31       Impact factor: 5.705

3.  Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis.

Authors:  Tomonori Hirashima; Hidekazu Suzuki; Norio Okamoto; Naoko Morishita; Tadahiro Yamadori; Motohiro Tamiya; Takayuki Shiroyama; Kanako Kurata; Ichiro Kawase
Journal:  Oncol Lett       Date:  2014-04-30       Impact factor: 2.967

4.  Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer.

Authors:  Jennifer S Davis; Erin Prophet; Ho-Lan Peng; Hwa Young Lee; Rebecca S S Tidwell; J Jack Lee; Anish Thomas; Eva Szabo; Shine Chang
Journal:  JNCI Cancer Spectr       Date:  2019-04-15

5.  Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs.

Authors:  Ying-Yuan Chen; Yi-Ting Yen; Wu-Wei Lai; Wei-Li Huang; Chao-Chun Chang; Yau-Lin Tseng
Journal:  Thorac Cancer       Date:  2021-09-08       Impact factor: 3.500

6.  Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine.

Authors:  Sevket Ozkaya; Serhat Findik; Adem Dirican; Atilla Güven Atici
Journal:  Exp Ther Med       Date:  2012-09-18       Impact factor: 2.447

7.  Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer.

Authors:  Khurum Khan; Gerard G Hanna; Lynn Campbell; Paula Scullin; Adnan Hussain; Ruth L Eakin; Jonathan McAleese
Journal:  Chin J Cancer       Date:  2013-08-28

8.  Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?

Authors:  Mélanie Deberne; Stanislas Ropert; Bertrand Billemont; Catherine Daniel; Jeanne Chapron; François Goldwasser
Journal:  BMC Cancer       Date:  2014-06-10       Impact factor: 4.430

9.  Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].

Authors:  Cheng-Jeng Tai; Chien-Kai Wang; Chen-Jei Tai; Ching Tzao; Yung-Chang Lien; Chih-Cheng Hsieh; Cheng-I Hsieh; Hong-Cheng Wu; Chih-Hsiung Wu; Chun-Chao Chang; Ray-Jade Chen; Hung-Yi Chiou
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

10.  Surgery and subsequent risk of non-small cell lung cancer recurrence: a meta-analysis of observational studies.

Authors:  Jia Hu; Huikai Miao; Rongzhen Li; Zhesheng Wen
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.